A PTC Therapeutics officer told the SEC about a plan to sell $105K of PTC Therapeutics shares around Oct 5, 2026. The filing says the shares were acquired as compensation.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 144 — Notice of Proposed Sale of Securities

All the details

Dates, kept separate

Planned sale date: Oct 5, 2026
Reporting period: Not applicable
Notice filed with the SEC: Oct 5, 2026

OfficerPlanned saleShares from pay

Context

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001959173-26-007274
Filed / recorded: Oct 6, 2026, 12:20 AM UTC

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Added to OQRO

Oct 7, 2026, 1:40 PM UTC

Parser

form144-v1

Data quality

Read from the record; company matched by name

Issuer

PTC THERAPEUTICS, INC.

Issuer CIK

1070081

Table

Non-derivative (Table I)

Transaction date

—

Shares / units

—

Price per share

—

Shares owned after

—

Ownership form

Direct

Amendment

Around the same time

Boulding Mark Elliott (Officer) plans to sell ~$28K of PTC Therapeutics, Inc.

Planned, from payFiled yesterday

Steele Glenn Jr Md PhdDirector

Filed 4d ago

12KShares · @ $11.23

Traded Sep 30 · filed 3 days later

Derivative exercise or conversion — not an open-market buy.

More Official record

Steele Glenn Jr Md Phd (Director) sold ~$782K of PTC Therapeutics, Inc.

Planned saleFiled 4d ago